Comparative evaluation of branch retinal vein occlusion treatment with ultra wide-field imaging guided peripheral scatter laser in combination with ranibizumab ( anti-VEGF for macular edema in BRVO) vs ranibizumab only in treatment naive cases.
Not Applicable
Completed
- Conditions
- Health Condition 1: null- BRVO with macular edema
- Registration Number
- CTRI/2018/03/012383
- Lead Sponsor
- AIIMS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 33
Inclusion Criteria
1.Diagnosed case of BRVO with macular edema with evidence of capillary non perfusion
2.Macular edema involving center of fovea
3.BCVA at baseline- 3/60-6/18 by Snellenâ??s visual acuity
4.Mean central subfield thickness > 300 micrometer by OCT at baseline visit
5.Informed consent
6.Media clarity, pupillary dilatation and patient cooperation sufficient for fundus photography
Exclusion Criteria
1. other ocular diseases like AMD eyes, diabetic retinopathy, disc pallor
2. recent CVA, MI or major ischemic event 3 months preceding baseline visit
3. known sensitivity to any anti-VEGF drugs and sodium fluorescein
4. previous macular or pan retinal photocoagulation
5.previous anti-VEGF treatment
6.no consent
7.patient not willing for follow up
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method BCVA ( snellens visual acuity and ETDRS)Timepoint: 1 month, 3 months, 6 months
- Secondary Outcome Measures
Name Time Method OCT <br/ ><br>number of ranibizumab injections <br/ ><br>contrast sensitivityTimepoint: 1 month, 3 months, 6 months